🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

POD24 a critical event in #MCL. A key group to identify and focus our efforts on. #lymsm nature.com/articles/s4140…

Very important editorial in The Lancet today. Please read. Supporting medical science in the USA - The Lancet thelancet.com/journals/lance…

Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma? - The Lancet Haematology thelancet.com/journals/lanha…

🚨Calling all @asco #ASCO25 annual meeting attendees! Come join us in person for our annual #MedEd CoP event!! 🔔 Saturday May 31st 🔔 7:30-9:30 am 🔔 Room S103 ‼️Keynote speakers: TwoOncDocs and Oncology Brothers!! Can’t wait to see you there!! 🥰

We are so excited for our keynote ASCO OncMedEdCoP #ASCO25 with Oncology Brothers - join us 7:30AM on Saturday May 31! 💫 Samantha Armstrong Karine Tawagi MD

The discovery of genetic subtypes of DLBCL is a major advance in taming the molecular heterogeneity of DLBCL, which otherwise acts as a barrier to precision medicine. ow.ly/qqrQ50VLFOZ #lymphoidneoplasia

Treating the untreatable - "Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure" Penn Medicine @nejm #immunotherapy nejm.org/doi/full/10.10…

Heme/Onc Med Ed Colleagues, ASCO Annual Meeting is almost here… let’s start Saturday AM together ASCO OncMedEdCoP! #HemeOncMed

Burnout among oncology and healthcare professionals is on the rise, but what can be done? CancerNetwork® spoke with Eric Winer, MD on ways to address burnout and improve well-being, incl findings published in Journal of Clinical Oncology. brnw.ch/21wSx4Z

📝 The phase I/II NP30179 study published in J Clin Oncol demonstrated that FD glofitamab was well tolerated and yielded durable responses in heavily pretreated patients with MCL. More news: LymphomaHub.com #lymphoma #lymsm #MedNews #MedEd

How are women shaping the future of lymphoma care? Join Kami J Maddocks, MD and Morgane Cheminant, MD, PHD for a deep dive into Mantle Cell Lymphoma + career insights! MedNewsWeek Women in Lymphoma - [email protected] Kami Maddocks #Lymphoma #WomenInMedicine Register now: hubs.li/Q03m47w_0

An Updated Understanding of Follicular Lymphoma Transformation ashpublications.org/blood/article/…

New malignancies and nonrelapse mortalities were rare, occurring in 4 and 2 patients each, and none was related to axi-cel. ow.ly/1MGx50VTZy3 #cartcell #cart #lymsm #lymphoma

Polatuzumab Vedotin, zanubrutinib and rituximab (Pola-ZR) achieved rapid and deep response in untreated frail and elderly DLBCL link.springer.com/article/10.100…

So much change in R/R #DLBCL over recent years! See the updated BSH - Haematology guidelines now online onlinelibrary.wiley.com/doi/10.1111/bj…

Transfusion provides vital supportive care for patients across many clinical settings, but high-quality evidence is not always available to guide our transfusion-related decision-making. ow.ly/FMO250VTzwE #redcellsironanderythropoiesis #transfusionmedicine Erica Wood

First-line axi-cel demonstrated an 86% complete response rate and 3-year PFS rate of 75% in efficacy-evaluable patients with high-risk LBCL. ow.ly/U10I50VTZ78 #lymphoma #lymsm #cart #cartcell

🚨Publication Alert! Yazeed Sawalha, MD has published "Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis" in Blood Cancer Journal 📖 Read here: nature.com/articles/s4140…

Optimizing Chimeric Antigen Receptor T-Cell Therapy for Mantle Cell Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Thrilled and honored to join this incredible group of Hematology/Oncology medical educators! Thanks to ASCO for this amazing opportunity #MedEd